生物股份(600201.SH)：全資子公司獲得中國合格評定國家認可委員會(CNAS)認可決定書
格隆匯4月8日丨生物股份(600201.SH)公佈，公司全資子公司金宇保靈生物藥品有限公司(“金宇保靈”)的生物安全三級動物實驗室在前期獲得中國合格評定國家認可委員會(CNAS)實驗室生物安全認可證書的基礎上，於2020年4月7日通過中國合格評定國家認可委員會(CNAS)不定期監督評審，獲得相關認可決定書。
機構名稱：金宇保靈生物藥品有限公司生物安全三級動物實驗室；機構註冊號：CNASBL0101
根據中國合格評定國家認可委員會(CNAS)的有關規定，CNAS祕書處對金宇保靈生物安全三級動物實驗室進行了不定期監督評審。經審定，CNAS做出以下決定：
一、對金宇保靈生物安全三級動物實驗室部分機構工作範圍變更予以確認。
二、允許金宇保靈生物安全三級動物實驗室按照《認可標識和認可狀態聲明管理規則》(CNAS-R01)的規定使用CNAS認可標識。本次中國合格評定國家認可委員會(CNAS)確認的部分工作範圍變更主要是金宇保靈生物安全三級動物實驗室新增布魯氏菌實驗活動相關內容，包括細菌分離、培養、鑑定和動物感染實驗。
中國合格評定國家認可委員會(CNAS)，是根據《中華人民共和國認證認可條例》的規定，由國家認證認可監督管理委員會批准成立並確定的認可機構，統一實施對認證機構、實驗室和檢驗機構等相關機構的認可工作，是國際認可論壇(IAF)、國際實驗室認可合作組織(ILAC)和亞太認可合作組織(APAC)的正式成員。CNAS認可已經融入國際認可互認體系，在國際認可活動中佔據重要地位。
金宇保靈生物安全三級動物實驗室此次新增布魯氏菌的相關工作範圍，將進一步擴展該實驗室高致病性病原微生物的研究種類，標誌着該實驗室已具備布魯氏菌相關實驗活動的條件和能力，為公司未來進行布魯氏菌研究提供必要的研發平台支撐，對豐富公司產品類型和提升相關疫苗研發能力具有積極作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
